Home › Calculator › FBIO Dividend Calculator 2026
FBIO Dividend DRIP Calculator 2026
66.67% YieldHealthcareFortress Biotech, Inc. · NASDAQ
Price: $3.00 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When FBIO pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your FBIO snowball 📈
$10,000 in FBIO → $1.6K in 10 years · $53.84/month
About Fortress Biotech, Inc. (FBIO) — Dividend Analysis 2026
Fortress Biotech, Inc. operates as a biopharmaceutical firm dedicated to the development and commercialization of a diverse range of pharmaceutical and biotechnology products. The company currently offers a portfolio of dermatological treatments. These include Ximino and Targadox, both formulated to address various forms of acne (ranging from moderate-to-severe inflammatory lesions to severe cases). Other products in this segment are Exelderm cream for fungal skin infections like ringworm and jock itch, Ceracade for dry skin conditions, Luxamend for wound care, and Accutane capsules for particularly severe, stubborn nodular acne. Its pipeline features several promising late-stage drug candidates, targeting a diverse range of medical needs. These include intravenous Tramadol for acute post-operative pain, CUTX-101 (an injection for Menkes disease), MB-107 and MB-207 for X-linked severe combined immunodeficiency, Cosibelimab for metastatic cancers, CK-101 for non-small cell lung cancer characterized by EGFR mutations, CAEL-101 for amyloid light chain (AL) amyloidosis, the Triplex vaccine for cytomegalovirus, and CEVA101 for critical traumatic brain injuries in adults and children. Furthermore, its earlier-stage research encompasses various investigational treatments such as MB-102 for blastic plasmacytoid dendritic cell neoplasm, MB-101 for glioblastoma, MB-104 for multiple myeloma and light chain amyloidosis, MB-106 for B-cell non-Hodgkin lymphoma, MB-103 for glioblastoma and metastatic breast cancer to the brain, MB-108, MB-105 for prostate and pancreatic malignancies, and BAER-101. In the preclinical phase, Fortress Biotech is exploring an array of novel therapeutic approaches. These comprise AAV-ATP7A and AVTS-001 (both gene-based therapies), the CK-103 BET inhibitor, CEVA-D and CEVA-102, CK-302 (an antibody targeting GITR), CK-303 (an antibody against CAIX), ConVax, and the ONCOlogues oligonucleotide platform. The company also actively engages in collaborative ventures with universities, research institutions, and other pharmaceutical organizations. Originally established in 2006, the entity operated as Coronado Biosciences, Inc. before rebranding as Fortress Biotech, Inc. in April 2015. Its corporate headquarters are situated in Bay Harbor Island, New York.
Compare FBIO with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full FBIO DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open FBIO position with:
🌍 FBIO Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold FBIO.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 66.67% | 63.87% | $6,667 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 56.67% | 53.87% | $5,667 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 53.34% | 50.54% | $5,334 / yr |
| 🇬🇧 UK ISA | 0% | 66.67% | 63.87% | $6,667 / yr |
| 🇬🇧 UK Taxable | 8.75% | 60.84% | 58.04% | $6,084 / yr |
| 🇨🇦 TFSA | 0% | 66.67% | 63.87% | $6,667 / yr |
| 🇨🇦 CA Taxable | 25% | 50.00% | 47.20% | $5,000 / yr |
| 🇦🇺 Super (pension) | 15% | 56.67% | 53.87% | $5,667 / yr |
| 🇦🇺 AU Taxable | 30% | 46.67% | 43.87% | $4,667 / yr |
| 🇩🇪 DE Taxable | 26.375% | 49.09% | 46.29% | $4,909 / yr |
| 🇫🇷 FR Taxable | 30% | 46.67% | 43.87% | $4,667 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 FBIO Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 FBIO Dividend Payment Schedule
FBIO pays quarterly — 4 times per year. Next ex-div: TBD.
📊 FBIO vs Healthcare Benchmarks
How FBIO compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for FBIO sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ FBIO Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2026-06-22 | 400,000 | — | — | ||
| A-Award | 2026-04-01 | 2,967 | $2.18 | $6.5K | ||
| A-Award | 2026-03-18 | 475,424 | — | — | ||
| A-Award | 2026-03-18 | 475,424 | — | — | ||
| A-Award | 2026-01-01 | 27,322 | — | — | ||
| A-Award | 2026-01-01 | 27,322 | — | — | ||
| A-Award | 2026-01-01 | 27,322 | — | — | ||
| A-Award | 2026-01-01 | 27,322 | — | — | ||
| A-Award | 2026-01-01 | 27,322 | — | — | ||
| A-Award | 2025-10-01 | 2,711 | $1.31 | $3.5K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the FBIO dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Fortress Biotech, Inc. (FBIO) is currently trading at $3.00, 96% below its 52-week high. The current dividend yield is 66.67% based on an annual payout of $2.00 per share.
FBIO (Fortress Biotech, Inc.) — 66.67% Dividend Yield Analysis
Fortress Biotech, Inc. (FBIO) is a healthcare stock currently trading at $3.00 with a dividend yield of 66.67%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings. Over the past 5 years, FBIO has grown its dividend at a compound annual rate of 50.0%.
- Above-average yield (66.67%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.
Latest FBIO News
LiveNews aggregated from public sources via Finnhub & RSS. For informational purposes only.